Fig. 1From: Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trialsDifference between dual therapy vs. monotherapy in FEV1 change from baseline. CI confidence interval, FEV1 forced expiratory volume at 1Â s, GOLD Global initiative for Chronic Obstructive Lung Disease, LABA long-acting beta-2 agonist, LAMA long-acting muscarinic antagonist, LSM least squares meanBack to article page